Sichuan Kelun Pharmaceutical 科伦药业
11 significant filings since 30 May 2026: 4 on buyback, 3 on pledge released and 1 on share issue, and 3 other kinds. The latest, on 2 Sep 2026: 关于公司控股股东部分股份质押及解除质押的公告.
自 30 May 2026 起有 11 份重大公告：buyback 4 份、pledge released 3 份、share issue 1 份，另有 3 类。最新一份（2 Sep 2026）：关于公司控股股东部分股份质押及解除质押的公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 29 Apr 2024 | 西南证券 | 杜向阳 | Outperform 增持 | ▲ | Buy 买入 |
| 11 Dec 2023 | 西南证券 | 杜向阳 | Buy 买入 | ▼ | Outperform 增持 |
| 1 Sep 2022 | 东吴证券 | 朱国广 | Outperform 增持 | ▲ | Buy 买入 |
| 16 Jul 2019 | 华金证券 | 周新明 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 东海证券 | 杜永宏 | Buy 买入 | 8 Sep 2026 | 2 | — |
| 西南证券 | 杜向阳 | Unrated | 31 Aug 2026 | 2 | — |
| 东吴证券 | 朱国广 | Buy 买入 | 27 Aug 2026 | 2 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 6 reports. 每行为该券商近十二个月的最新研报；6 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。